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SelectHIV Antibodies Return to Clinical TrialsAlmost 35 years after the first cases of immunodeficiency
associated with HIV were reported, the HIV infection has
spread worldwide, reaching nearly 40 million people. Antire-
troviral therapy has evolved at a fast pace, and combined
drug therapy is now part of the standard care of HIV-infected
individuals, successfully preserving their health and lifespan
in most cases. The endless capacity of the virus to subvert
the host immune response and to persist in a latent state
nonetheless has been frustrating and challenges the expec-
tation that a definitive cure and an effective vaccine would be
easily achievable.
Immunotherapy using combinations of monoclonal anti-
bodies that are injected in infected subjects to neutralize
the virus and stimulate immune-mediated killing of infected
cells was a particularly promising concept. However, it failed
to demonstrate any efficacy in initial pre-clinical and clinical
studies in part due the ability of the virus to rapidly mutate
and escape the antibodies. Caskey et al. (2015) now return
to this original concept and report the initial results of a
first-in-humans dose escalation phase 1 clinical trial using
the 3BNC117 anti-HIV antibody in infected and uninfected
people. The antibody infusion is safe and well-tolerated,
and a single injection is able to reduce the viral load of in-
fected subjects by 0.8–2.5 log10 for up to 1 month. What is
different about the 3BNC117 antibody that gives it an advan-
tage over the virus?
In recent years, it has become clear that a small fraction
of people living with HIV-1 develop a flavor of antibodies
with a very particular feature: they are very potent at
neutralizing different variants of the HIV (West et al.,
2014). These molecules, termed broadly neutralizing anti-
bodies (bNAbs), usually target regions of the viral envelope
that are conserved in viral isolates from different origins,Several potent anti-HIV broadly neutralizing antibodies have been
identified to date and have the potential to be used in strategies to
treat and prevent HIV spread in combination with other types of
drugs. Image from iStockphoto/Eraxion.and therefore, they are able to bind and neutralize a large
fraction of variants of the virus. The evolution in the
methods to isolate and clone antibodies allowed re-
searchers to identify several bNAbs and study their charac-
teristics and the sites that they bind to in the virus. In
contrast to the first generation of monoclonal antibodies
that were ineffective as HIV-1 immunotherapy, 3BNC117
is a very potent broadly neutralizing antibody, capable of
neutralizing 195 out of 237 different HIV-1 strains (Scheid
et al., 2011). Its target is the CD4-binding site on the viral
protein gp120, the portion of the molecule that interacts
with the CD4 receptor in the host cells. This interaction is
crucial for the initial stages of the viral infection, and there-
fore, it is a conserved site among different strains of the vi-
rus and it is one of the few sites in the protein that are not
decorated with the glycan shield that protects it against
antibody recognition.
Broadly neutralizing antibodies are the almost perfect tool
against not just HIV-1 but also other highly mutagenic viruses
such as influenza, and stimulating individuals to produce
them with vaccines is a current goal. The problem is that
they are very difficult to elicit under natural conditions. The
study of their properties shows that they accumulate a large
number of somatic mutations, deletions, and insertions that
are infrequent in conventional antibodies (West et al.,
2014). Likely, they take many years to arise during natural
infection, and the reasons why a few people develop
them—but the majority of the infected humans does not—
are unknown. Identifying bNAbs that are naturally generated
is an important strategy to overcome this barrier, as they
could be used to treat or promote passive protection against
the infection. In fact, the combination of different potent
broadly neutralizing antibodies suppresses HIV-1 viral load
in humanized mice. Additionally, therapy with single bNAbs
can suppress viremia in non-human primates infected with
a simian immunodeficiency virus that is closely related to
the human virus (West et al., 2014).
The antibodies are only able to suppress HIV infection for
a limited period in experimental models and in the new
clinical trial. In humanized mice and non-human primates,
the viremia remains suppressed as long as the concentra-
tion of the antibody in the blood remains within therapeutic
range. In the new clinical trial, 3BNC117-resistant viruses
emerged in a fraction of the patients 28 days after the
infusion (Caskey et al., 2015). Still, the fact that some indi-
viduals did respond to immunotherapy, even if transiently,
renews the hopes that this strategy is worthy of pursing. As
with antiretroviral drugs, combination of different reagents
may prove to be more efficacious than single-antibody
therapy in humans. In addition, engineering bNAbs to
improve their effector functions—for instance, antibody-
dependent cellular cytotoxicity (Bournazos et al., 2014)—
or to increase the affinity for their targets could also
contribute to their clinical efficacy. Finally, antibodies are
expensive to produce, so it is unlikely that they will
become the first line of treatment for patients with HIV inCell 161, April 23, 2015 ª2015 Elsevier Inc. 423
monotherapy. However, in combination with drugs that can
activate latent viruses, interfering and potentially clearing
the latent HIV-1 reservoir (Halper-Stromberg et al., 2014),
they may be critical to development of the long-sought
cure for HIV infection.
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